대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Nephrotoxin Stewardship and AKI Prevention
저자	Sandra Kanes Gill
출판정보	2024; 2024(1):
키워드
초록	Drug associated acute kidney injury (D-AKI) contributes to 20-30% of kidney related events in intensive care units (ICU). Drugs are a modifiable exposure providing an opportunity for interventions to prevent AKI occurrence or ameliorate AKI severity and promote kidney health. Consistent application of contemporary definitions for drug related kidney diseases should be adopted as it provides homogenous utility in pharmacovigilance and pharmacoepidemiology efforts.(PMID: 37946280) “Nephrotoxin stewardship is a set of coordinated patient care management strategies to improve the use of nephrotoxins, renally eliminated drugs and kidney disease treatments with the goal of enhancing patient outcomes through safe medication use, ensuring kidney health and avoiding unnecessary costs.” (PMID: 33752857) Identifying renally eliminated drugs and nephrotoxins to target for surveillance by standardizing focused lists is the first step in risk assessment and prevention. Nephrotoxin stewardship extends beyond single drugs for surveillance to consideration of drug burden and drug-drug interactions. The next step in nephrotoxin stewardship is hypervigilant inspection of risk and impending harm using traditional functional biomarkers and novel damage biomarkers. Approaches that have been used to identify risk for D-AKI are three drug nephrotoxin alerting (drug burden) and use of stress/damage biomarkers indicating risk before overt damage when serum creatinine rises. Strategies for nephrotoxin stewardship should be implemented in a cost-conscious manner. The key to preventing D-AKI is a coordinated nephrotoxin stewardship strategy.
원문(PDF)	PDF 원문보기

목록

위로가기